FEBS Letters · 2003 · 58 citations · 23 references
MedicineBiotechnologyMolecular GeneticsGene DeliveryGene ExpressionGene TherapyIntramuscular Drug DeliveryMuscle PathologyMuscle TissueMuscular DystrophyOligonucleotide Delivery2'-O-methyl RnaAntisense RnasExon Skipping TherapyIn Vivo DeliveryIn Vivo StudiesMuscle Gene DeliveryMuscle Gene TherapyPhosphorothioate Modification
The use of antisense oligonucleotides (AOs) to induce exon skipping leading to generation of an in-frame dystrophin protein product could be of benefit in around 70% of Duchenne muscular dystrophy patients. We describe the use of hyaluronidase enhanced electrotransfer to deliver uncomplexed 2'-O-methyl modified phosphorothioate AO to adult dystrophic mouse muscle, resulting in dystrophin expression in 20-30% of fibres in tibialis anterior muscle after a single injection. Although expression was transient, many of the corrected fibres initially showed levels of dystrophin expression well above the 20% of endogenous previously shown to be necessary for phenotypic correction of the dystrophic phenotype.
23
The Molecular Basis of Muscular Dystrophy in the <i>mdx</i> Mouse: a Point Mutation
Piotr Siciński, Yan Geng, Allan S. Ryder-Cook et al. · Science · 1989 · 1.2K citations
L. Skordis, Matthew G. Dunckley, Baigong Yue et al. · Proceedings of the National Academy of Sciences · 2003 · 271 citations · Full text